Two recent studies were published in the Journal of American Medical Association about a new drug for smoking cessation (Gonzales et al, 2006; Jorenby et al 2006). Unlike other approved treatments for smoking cessation including nictotine replacement therapy, or selectively inhibit the reuptake of dopamine (Bubrorpion), Chantix is a partial agonist of the alpha 4 Beata 2 nictotinic acetylcholine receptor.
In the study both of these studies, Chantix's efficacy exceeded buproprion SR and placebo (Jorenby et al, 2007). During the last four weeks of treatment, 43.9% of participants in the varenicline group were abstinent from smoking compared with 17.6% and 29% in the placebo and buprioprion SR groups respectively.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47-55.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63.
http://www.chantix.com/
No comments:
Post a Comment